
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
The incidence rates for various foodborne illnesses have stabilized after a period of decline, according to a report published in the April 11 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.






